Genfit S.A.
GNFT.PA·Paris·Healthcare
11.140.00 (0.00%)today
As of Nov 4, 5:35 PM CET · May be delayed up to 15 min · EUR
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close11.14
Open11.24
Day range10.8611.60
52-week range3.4015.48
Off day high−3.97%
Off 52-week high−28.04%
Volume247.59K
Avg. volume (3M)343.75K
Market cap557.35M
EPS (TTM)-2.03
Forward P/E61.89
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.19
Shares outstanding50.03M
Short interest—
Earnings dateSep 28, 2026
Analyst target18.88
Profit margin−171.68%
Against its peers
Compare in full ›| GNFT.PA | GYRE | IVA | AGMB | AVBP | KROS | |
|---|---|---|---|---|---|---|
| Market cap | 557.35M | 470.79M | 914.17M | 337.35M | 665.16M | 214.73M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 61.9 | 74.0 | -5.2 | -3.4 | -3.6 | -1.6 |
| Price/book | -11.5 | 4.4 | 13.8 | 2.7 | 1.8 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +214.77% | −39.51% | −7.42% | −53.24% | −26.64% | −33.02% |
| Today | 0.00% | 0.00% | −3.97% | 0.00% | +3.61% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GNFT.PA news ›Ipsen places €480m bet on Genfit's liver drug elafibranor
Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and now has the help of fellow French pharma group…
From the 4Search news index, newest first.
In the news
1mentions in 30 days
1with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Most coverage from
- pharmaphorum.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.